GlassScriptPhysician profile
Chandra B Armstrong
NPI 1376625053
$8,222.09
in general payments reported to CMS, 2019-2025
25 companies · $824 in 2025
The $824 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $801 · 2021: $839 · 2022: $802 · 2023: $2,359 · 2024: $1,540 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,502 · Travel and Lodging: $1,077 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,502.44 |
| Travel and Lodging | $1,076.82 |
| Education | $144.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,335.12 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Genentech USA, INC. | $1,125.77 | 2023 | |
| Abbvie INC. | $1,063.09 | 2019-2025 | Ubrelvy, Vraylar |
| Lilly USA, LLC | $973.62 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $851.27 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $808.77 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $499.49 | 2019-2024 | Jardiance, Synjardy |
| Astellas Pharma US INC | $476.08 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $184.07 | 2019-2024 | Xarelto |
| Allergan, INC. | $176.58 | 2019-2020 | |
| Abbott Laboratories | $133.85 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $123.59 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $118.16 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Otsuka America Pharmaceutical, INC. | $68.05 | 2024-2025 | Rexulti |
| Pfizer INC. | $48.35 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.68 | 2019-2023 | Repatha |
| Amarin Pharma, INC. | $47.38 | 2019-2020 | |
| Glaxosmithkline, LLC. | $46.79 | 2024-2025 | Trelegy Ellipta, Shingrix |
| Coloplast Corp | $30.23 | 2019 | |
| Exact Sciences Corporation | $19.79 | 2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $17.02 | 2025 | Contrave |
| Echosens North America, INC. | $15.30 | 2024 | Fibroscan |
| Teva Pharmaceuticals USA, INC. | $12.04 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.